Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Mannosidosis Indication Strategy Report 2026: MAN2B1, Trials and Deals
30 July 2026
2026 Mannosidosis indication strategy covering epidemiology, MAN2B1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation Indication Strategy Report 2026: DARS2, Trials and Deals
30 July 2026
2026 Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation indication strategy covering epidemiology, DARS2 biology, active…
Latest Hotspot
8 min read
Hypomyelination with atrophy of basal ganglia and cerebellum Indication Strategy Report 2026: TUBB4A, Trials and Deals
30 July 2026
2026 Hypomyelination with atrophy of basal ganglia and cerebellum indication strategy covering epidemiology, TUBB4A biology, active trials, transactions, unmet…
Latest Hotspot
8 min read
Arginine:glycine amidinotransferase deficiency Indication Strategy Report 2026: GATM, Trials and Deals
30 July 2026
2026 Arginine:glycine amidinotransferase deficiency indication strategy covering epidemiology, GATM biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia Indication Strategy Report 2026: CSF1R, Trials and Deals
30 July 2026
2026 Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia indication strategy covering epidemiology, CSF1R biology, active trials,…
Latest Hotspot
8 min read
POLR3-related leukodystrophy Indication Strategy Report 2026: POLR3A, Trials and Deals
30 July 2026
2026 POLR3-related leukodystrophy indication strategy covering epidemiology, POLR3A biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Glucose transporter type 1 deficiency syndrome Indication Strategy Report 2026: SLC2A1, Trials and Deals
30 July 2026
2026 Glucose transporter type 1 deficiency syndrome indication strategy covering epidemiology, SLC2A1 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Cerebral folate deficiency Indication Strategy Report 2026: FOLR1, Trials and Deals
30 July 2026
2026 Cerebral folate deficiency indication strategy covering epidemiology, FOLR1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Sepiapterin reductase deficiency Indication Strategy Report 2026: SPR, Trials and Deals
30 July 2026
2026 Sepiapterin reductase deficiency indication strategy covering epidemiology, SPR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Dopamine transporter deficiency syndrome Indication Strategy Report 2026: SLC6A3, Trials and Deals
30 July 2026
2026 Dopamine transporter deficiency syndrome indication strategy covering epidemiology, SLC6A3 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Segawa syndrome Indication Strategy Report 2026: GCH1, Trials and Deals
30 July 2026
2026 Segawa syndrome indication strategy covering epidemiology, GCH1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Developmental and epileptic encephalopathy 2 Indication Strategy Report 2026: CDKL5, Trials and Deals
30 July 2026
2026 Developmental and epileptic encephalopathy 2 indication strategy covering epidemiology, CDKL5 biology, active trials, transactions, unmet need, competition…